Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
Article
[키워드] 1:1
95% CI
Acute kidney injury
acute respiratory distress
addition
all-cause mortality
all-cause mortality rate
Analysis
antibody
assigned
Belgium
Block randomisation
Brazil
C5a
Critically ill
defined
determine
died
dose
double-blind
eligible
excluded
France
Germany
hazard ratio
hospital
hospital discharge
IMPROVE
intravenously
intubation
invasive
Invasive mechanical ventilation
ITT analysis
Kaplan-Meier analysis
matching placebo
mechanically ventilated patient
monoclonal antibody
Mortality
multicentre
Netherlands
Older
one patient
outcome
PaO
participant
Patient
patient population
phase 2 trial
phase 3 trial
Placebo
placebo-controlled
Pneumonia
primary analysis
Primary outcome
random assignment
randomised
Randomly
receive
receiving
reduced
Registered
reported
Research
Russia
Safe
safety analysis
SARS-COV-2 infection
Septic shock
shown
significant decrease
significantly
South Africa
Standard of care
survival
TEAE
the placebo group
therapy
Treatment
treatment-emergent adverse event
variant
vilobelimab
viral infections
was performed
with COVID-19
[DOI] 10.1016/S2213-2600(22)00297-1 PMC 바로가기 [Article Type] Article
[DOI] 10.1016/S2213-2600(22)00297-1 PMC 바로가기 [Article Type] Article